RET Inhibitor Before Surgery for Certain Advanced Thyroid Cancers
Studies a RET-blocking drug given before surgery in people with advanced thyroid cancer.
Plain-language title generated from the registry record
Registry title: RET Inhibitor for Neoadjuvant Therapy in Locally Advanced RET-altered Thyroid Cancer
Key facts
- Where
- Shanghai, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 14 and 80 years old?
Source: NCT06530316, who can take part
Where in China
- Fudan Univeristy Shanghai Cancer CenterShanghai, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Fudan University
- Trial code
- NCT06530316
- Record updated
- 2 August 2024
- Original description
This study is a multicenter observational study. Patients receive neoadjuvant therapy with RET inhibitors in the real world, and those who can undergo surgery after neoadjuvant therapy receive surgical treatment. The aim of the study is to determine the efficacy and safety of RET inhibitors for neoadjuvant therapy in locally advanced RET-altered thyroid cancer.Read full original descriptionShow less
The Efficacy and Safety of RET Inhibitor for Neoadjuvant Therapy in Locally Advanced RET-altered Thyroid Cancer: a Real-world Study
This study is a multicenter observational study. Patients receive neoadjuvant therapy with RET inhibitors in the real world, and those who can undergo surgery after neoadjuvant therapy receive surgical treatment. The aim of the study is to determine the efficacy and safety of RET inhibitors for neoadjuvant therapy in locally advanced RET-altered thyroid cancer.
Inclusion: Patients voluntarily join this study and sign an informed consent form; Age: ≥ 14 years old, male or female not limited; Locally advanced thyroid cancer diagnosed by histopathology, including papillary thyroid carcinoma, medullary thyroid carcinoma, follicular thyroid carcinoma, poorly differentiated/poorly differentiated thyroid carcinoma, etc; RET alterations, including fusion and mutations; The definition of locally advanced thyroid cancer meets at least one of the following criteria:; Local advanced thyroid cancer with estimated surgical difficulty and inability to R0/1 resection; T4 thyroid cancer defined by AJCC: any size of tumor primary lesion or regional lymph node infiltration beyond the thyroid capsule to subcutaneous soft tissue, larynx, trachea, esophagus, or recurrent laryngeal nerve, tumor invasion of pre vertebral fascia or wrapping around carotid or mediastinal blood vessels; According to the imaging score, the resectable probability is less than 80% based on CT; At least one measurable lesion; For patients with distant metastasis, researchers need to determine whether patients would benefit from surgery; Patients voluntarily undergo tumor tissue biopsy/surgery during enrollment and withdrawal; Normal function of major organs.
Exclusion: Previously used RET inhibitors; There are multiple factors that affect the absorption of oral medication, such as inability to swallow, nausea and vomiting, chronic diarrhea, and intestinal obstruction; The patient refuses to undergo tumor tissue biopsy or surgery; Patients who are unsuitable for RET inhibitors or surgery.